Posted by Michael Wonder on 04 Oct 2018
ICER review highlights the clinical benefits of using anti-androgen therapies to treat earlier stage prostate cancer
4 October 2018 - Midwest CEPAC’s vote on value reflects uncertainty around duration of treatment with anti-androgens.
The ICER today released a Final Evidence Report and Report-at-a-Glance on three anti-androgen therapies for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC): abiraterone acetate (Zytiga, Janssen Biotech, Inc; a separate formulation [Yonsa, Sun Pharma] was not evaluated), enzalutamide (Xtandi, Astellas Pharma, Inc.), and apalutamide (Erleada, Janssen Biotech, Inc.).
ICER’s report was reviewed at a September 2018 public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), one of ICER’s three independent evidence appraisal committees. During the meeting, the Council found evidence sufficient to show a net health benefit of treating nmCRPC with either apalutamide or enzalumatide, compared to androgen deprivation therapy (ADT) alone. However, the Council found evidence insufficient to show a net health benefit for treating with abiraterone acetate.
